India's Tejas crashed at the Dubai Air Show. Officials to soon share details. Times Now brings you the exam moment of Tejas Crash. Watch the video to know more. Explained: Why billionaire Lakshmi ...

Abbott’s roughly $21 billion acquisition of cancer screening firm Exact Sciences lays out the company’s future strategy. Analysts said the acquisition not only marks Abbott’s foray into cancer ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...

Good morning, and thank you for standing by. Welcome to Abbott's conference call. [Operator Instructions]. This call is being recorded by Abbott. With the exception of any participants' questions ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Abbott has agreed to acquire cancer test-maker Exact Sciences for about $21 billion. Exact Sciences makes the Cologuard noninvasive screening test for colorectal cancer. The company also makes tests ...

Exact Sciences, one of Madison’s largest biotech companies, has agreed to be acquired by Abbott Laboratories for $23 billion, the Illinois-based company announced Thursday.

Thursday’s news that Abbott Labs is buying Madison-based Exact Sciences for $23 billion caps a year in which Exact Sciences already made the headlines multiple times.